Ethiopia is aggressively pursuing pharmaceutical independence, viewing it as essential for national security and sovereignty. The Armauer Hansen Research Institute (AHRI) is central to this strategy, providing advanced laboratory and bioequivalence services. Driven by lessons from the COVID-19 pandemic, the country has drastically cut import reliance, with domestic production now meeting 44% of demand, up from over 90% dependency. The nation aims to reach 55% domestic production soon and is developing the "ShieldVax Enterprise" to become a vaccine manufacturing hub, targeting "End-to-End" production. With a 58% import substitution rate in manufacturing over the last nine months, Ethiopia is making significant strides toward its five-year goal of full self-sufficiency.